Your Source for Venture Capital and Private Equity Financings

ADARx Pharmaceuticals Inks $46M Series B-1

SAN DIEGO, CA, ADARx Pharmaceuticals, a clinical stage biotechnology company, announced the close of a $46 million Series B-1 financing.
ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the close of a $46 million Series B-1 financing to advance its drug development pipeline as the Company's first product enters the clinic.

The Series B-1 was led by Ascenta Capital with the current syndicate of OrbiMed Advisors, SR One Capital Management, Lilly Asia Ventures, and Sirona Capital all participating in the financing.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors

Featured Reading